Abstract
The effective construction of structurally homogeneous glycosides is requisite in oligosaccharide assembly and the development of carbohydrate‐based drugs. A fluorine‐mediated stereoselective Ferrier‐type glycosylation is reported herein. Glycals are pre‐decorated with photo‐2‐difluoroalkylation and reacted with diverse acceptors to obtain exclusively α‐selective Ferrier rearrangement products. This procedure can tolerate extensive substrates and achieve good yields. Subsequent gram‐scale and oligosaccharide syntheses further demonstrate the applicability and practicality of this strategy. Detailed density functional theory studies demonstrate the predominant stereoselectivity of the glycosylation process.
Keywords: difluoroalkylation, ferrier‐type reaction, stereoselective glycosylation
A fluorine‐mediated stereoselective Ferrier‐type glycosylation is reported. Glycals are pre‐decorated with photo‐2‐difluoroalkylation and reacted with diverse acceptors to obtain exclusively α‐selective Ferrier rearrangement products.

1. Introduction
Carbohydrates are ubiquitous natural biomolecules, ranging from cellular energy sources to molecular recognition, and are leading compounds for drug and vaccine discovery.[ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 ] Increasing our understanding of these functional molecules demands significant amounts of these materials for biological, medicinal, and pharmacological studies.[ 9 , 10 , 11 , 12 ] Over the past decades, considerable research has been attributed to developing new glycosylation methods, especially those with high stereoselectivity (neighboring participation,[ 13 , 14 , 15 , 16 , 17 ] remote group participation,[ 18 , 19 , 20 , 21 , 22 , 23 , 24 ] conformation control,[ 25 , 26 , 27 , 28 ] solvent effect,[ 29 , 30 , 31 , 32 ] etc.[ 33 , 34 , 35 , 36 , 37 ]).
2,3‐Unsaturated glycosides and 2,3‐dideoxyglycosides are widely found in natural products and exhibit excellent antitumor and antibacterial activities.[ 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 ] First discovered in the 1960s, Ferrier‐type glycosylation reactions have become useful processes for direct access to 2,3‐unsaturated glycosides and subsequent convenient transformation to 2,3‐dideoxyglycosides or their analogs,[ 46 , 47 , 48 , 49 , 50 , 51 ] a widely used chiral intermediate in the preparation of biologically active compounds (Figure 1a).[ 41 , 42 , 52 , 53 , 54 ] However, most reported methods only offer modest stereoselectivity caused by the intrinsic effect. In recent years, carbohydrate researchers have focused on well‐designed glycosyl donors, leaving groups, and catalysts to improve the poor stereoselectivity in Ferrier rearrangement reactions. Most of the reported literatures often involve the Palladium catalysis for stereo‐control of Ferrier glycosylation products via “inner” or “outer” processes (Figure 1b).[ 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 ] Even so, designing a facile and efficient stereoselective Ferrier‐type glycosylation remains a long‐standing challenge in glycochemistry.
Figure 1.

Research background of this work. a) Selected biologically active 2,3‐unsaturated glycosides. b) Pd‐catalyzed Ferrier‐type glycosylation. c) Stereoselective glycosylation of difluoromethylated glycal.
The introduction of fluorine into a molecule at a selective site has been exploited extensively in drug design and catalyst development.[ 64 , 65 , 66 , 67 , 68 , 69 , 70 ] Fluorination is widely recognized to modulate metabolic stability, bioavailability, and protein‐binding affinity in carbohydrate‐based molecules, as demonstrated in numerous studies.[ 71 , 72 , 73 , 74 , 75 ] Fluorinated carbohydrates have notably served as chemical probes for molecular recognition.[ 76 , 77 , 78 , 79 ] In asymmetric synthesis, fluorinated molecules show great potential in orienting the reactivity of substrates and the development of highly stereo‐discriminating catalysts.[ 80 , 81 , 82 , 83 ] In addition, Gilmour et al. found that 2‐fluorohexose and 3‐fluorosialic acid donors showed remarkable stereoselectivity during glycosylation.[ 84 , 85 , 86 ] Karban et al. also achieved similar stereoselective effects using 3‐ and 4‐fluoro analogs as donors.[ 87 , 88 , 89 , 90 ] These studies shed light on the use of fluorine in configuration; however, the potential of polyfluoro‐substitution via glycosylation remains unclear. Here, we envisaged a mild and practical method for stereoselective Ferrier‐Type glycosylation based on 2‐difluoromethylated glycals, as well as the efficient construction of fluorine‐bearing glucosides (Figure 1c).
2. Results and Discussion
2.1. The Reaction Condition Screening
We began our investigation with the proof‐of‐concept of stereoselective Ferrier‐type glycosylation based on 2‐difluoromethylated glycals (Table 1 ). The model reaction was conducted using glycal 1a as the glycosyl donor and the alcohol i PrOH as the glycosyl acceptor. Upon extensive condition screening, BF3·Et2O was deemed the optimal promoter, generating the desired Ferrier‐Type product 2a with exclusive α‐selectivity in CH2Cl2 (Table 1, entry 1). Both the promoter and solvent can affect the reaction results (Table 1, entry 2; Tables S1 and S2, Supporting Information). Moreover, the promoter proved to be essential to our reaction outcome, which impaired the yield at high and low dosages (Table 1, entries 5,6; Table S3, Supporting Information). The temperature and time also had some influence on the yield, with 0 °C and 30 min being selected as the ideal parameters (Table 1, entries 3,4; Tables S4 and S5, Supporting Information). Decreasing the amount of donor reduced the yield, indicating the potential side reaction of the vulnerable donor catalyzed by BF3·Et2O (Table 1, entries 7,8; Table S6, Supporting Information). Fluorine substituents proved to be essential to our reaction outcome. According to the control experiments, fluorine‐containing donors 1a, 1b, and 1c afforded α stereoselective products (Table 1, entries 1, 9, and 10), while the fluorine‐free donors 1d and 1e provided products with poor stereoselectivity (Table 1, entries 11,12). The initial comparative experiments suggested that stereoselective Ferrier‐type glycosylation could be achieved with 2‐fluoroalkylated glycals.
Table 1.
Reaction optimization and proof‐of‐concept.
| |||
|---|---|---|---|
| Entry a) | Deviation from above | 2 (Yield) b) | α/β ratio c) |
| 1 | none | 2a (90%) | >20:1 |
| 2 | THF | 2a (15%) | >20:1 |
| 3 | at ‐5 °C | 2a (68%) | >20:1 |
| 4 | at 5 °C | 2a (81%) | >20:1 |
| 5 | BF3·Et2O (0.15 mmol) | 2a (65%) | >20:1 |
| 6 | BF3·Et2O (0.25 mmol) | 2a (71%) | >20:1 |
| 7 | 1a (0.05 mmol) | 2a (49%) | >20:1 |
| 8 | 1a (0.10 mmol) | 2a (73%) | >20:1 |
| 9 | 1b instead of 1a | 2b (65%) | >20:1 |
| 10 | 1c instead of 1a | 2c (82%) | >20:1 |
| 11 | 1d instead of 1a | 2d (79%) | 4:1 |
| 12 | 1e instead of 1a | 2e (72%) | 3:1 |
Reaction conditions: glycal 1 (0.20 mmol), i PrOH (0.10 mmol), BF3·Et2O (0.20 mmol) at 0 °C under an argon atmosphere and reacted for 30 min;
Isolated yield;
The α/β ratio was determined by the 1H NMR analysis of the crude reaction mixture.
2.2. The Scope of Substrate
2.2.1. Preparation of 2‐Fluoroalkylated Glycals
To test the universality of stereoselective Ferrier‐glycosylation in the fluorine‐bearing glycal, we first constructed a series of 2‐difluoroalkylated glycals by photoredox reaction (Figure 2a). Different types of fluorinated glycals (e.g., D‐glucal, d‐galactal, L‐rhamnal, D‐arabinal and d‐allose) provided the corresponding products in moderate to high yields (51% to 94% yields, 18 examples), and gram scale synthesis of this 2‐difluoroalkylation can also be achieved (1a, 1g, 1h, and 1m).
Figure 2.

Substrate scope with yields of the isolated products. [a] Standard conditions: glycal (0.10 mmol), BrCF2CO2Et (0.30 mmol), fac‐Ir(ppy)3 (0.5 mol%), dry DMF (2 mL), Ar, rt. [b]4‐ClBz refers to 4‐chlorobenzoyl. [c]Standard conditions: difluoroalkylated glycal donor (0.20 mmol), acceptor (0.10 mmol), BF3·Et2O (0.20 mmol), dry CH2Cl2 (2 mL), Ar, 0 °C.
2.2.2. Scope of Ferrier‐Glycosylation
With the optimal conditions in hand, we next investigated the scope of Ferrier glycosylation. Under standard reaction conditions, both primary and secondary alcohols successfully deliver the glycosides 3a–3j in good yields with excellent stereoselectivity (Figure 2b). For highly active methanol and ethanol compounds, which usually offer poor glycosylation stereoselectivity, the desired Ferrier‐type products were obtained (3a–3d). Acceptors with aryl rings (benzyl alcohol and phenol) also gave α‐only products (3k,3l). Additionally, methyl‐, acetyl‐, and 4‐chlorobenzoyl‐protected donors were well‐tolerated to give glycosides in good yields (3b, 3h, 3k).
Next, we applied our established glycosylation protocol to sugar acceptors and natural products. As shown in Figure 3a, the reaction occurred smoothly under standard conditions, affording the desired α‐stereoselective products (4a‐‐4v). The reaction occurred in 2‐difluoroalkylated glucals and galactals with various protecting groups, giving high yields, while rhamnal and arabinal were identified as suitable substrates, delivering modest yields. This impaired performance may be due to their high reactivity, making them vulnerable to promoters. Glycals containing electron‐withdrawing groups (e.g., Ac─ and Bz─) always produced high yields compared to those containing electron‐donating groups (e.g., Bn─ and Me─). In addition, reactions with different kinds of sugar acceptors were also permissible and delivered the desired glycosides in satisfactory yields. Lastly, we focused on our glycosylation study in the late‐stage modification of natural products and drugs. Menthol and citronellol have specific aromas and are used as refreshing agents and antibacterial drugs to achieve the expected glycosylation products (4s and 4t). Steroids with complex structures were also well tolerated during the reaction (4u and 4v), which further supported the practicability of our fluorine‐mediated stereoselective Ferrier‐type glycosylation. In addition, gram scale synthesis (4a) also demonstrated the method's reliability of this reaction. Moreover, it should be noted that the product configuration of d‐glucals, d‐galactals and l‐rhamnals was analyzed as the α isomer while the d‐arabinals gave the β isomers. Such a situation of d‐arabinals may be responsible to its more stable 1,4‐trans conformation. These results have been further confirmed by X‐ray structure (4f, 4l, and 4k) and NMR NOESY experiments using several representative structures (Figures S1–S4, Supporting Information).
Figure 3.

a) Substrate scope with yields of isolated products. [a]Standard conditions: difluoroalkylated glycal donor (0.20 mmol), acceptor (0.10 mmol), BF3·Et2O (0.20 mmol), dry CH2Cl2 (2 mL), Ar, 0 °C. [b]0.40 mmol BF3·Et2O was used. [c]CDCC: 2474200. The single crystal belongs to 4f‐OH, which undergoes the deacetylation of 4f (see Figure S4, Supporting Information). b) One‐pot trisaccharide synthesis. Reaction conditions: a. donor 2l (0.30 mmol), acceptor 5a (0.15 mmol), BF3·Et2O (0.60 mmol), dry CH2Cl2 (2 mL), Ar, 0 °C; b. acceptor 5b (0.15 mmol), AgOTf (0.30 mmol), p‐TolSCl (0.20 mmol), TTBP (0.18 mmol), dry CH2Cl2 (3 mL), Ar, −78 °C.
2.3. Synthetic Presentation
To further expand the synthetic potential of this method, the one‐pot synthesis of an oligosaccharide was presented in our work (Figure 3b). The 2‐difluoroalkylated donor 1g was first reacted with acceptor 5a to furnish the disaccharide within 3 h under Ferrier‐type glycosylation. The subsequent in situ “pre‐activation” of the Ferrier‐type disaccharide at −78 °C followed by the addition of acceptor 5b effectively delivered the trisaccharide 5c in moderate yield (83%, two steps). These results further demonstrated the application of our method in oligosaccharide synthesis.
2.4. Mechanism Studies
Control experiments were conducted to investigate the influence of substituents at the C3, C4, and C5 positions on product configuration (Figures 4a,b; S5, Supporting Information). Comparison of glycosylation outcomes among D‐glucals (1a, 1f, 1g), D‐alloses (1s, 1t, 1u), and D‐galactals (1j, 1k, 1l) revealed that the bond orientation at the C3 and C4 positions of the donor does not significantly affect stereoselectivity. In contrast, the substituent at the C5 position plays a critical role, leading to the predominant formation of 1,5‐trans glycoside products. Notably, D‐arabinals featuring a free C5 position afforded 1,4‐trans glycoside products, which can be rationalized by the favorable conformation of the pyranose ring. Based on these control experiments, a possible SN2’‐type mechanism involving the C3‐leaving group was ruled out.[ 91 ]
Figure 4.

a) Control experiments. b) Reaction process of different sugar types. c) Proposed mechanism of donor activation by BF3·Et2O. d) DFT calculation of the glycosylation process. Glycal 1a and acceptor i PrOH were used in computational experiments. Energy measurements were expressed in kcal mol−1.
To gain further insight into the stereoselective Ferrier‐type glycosylation process, density functional theory (DFT) calculations were performed using D‐glucal 1a. Similar to the classical Ferrier type I glycosylation, the reaction proceeds in two steps. Initially, the 2‐difluoroalkylated donor is activated. As illustrated in Figure 4c, the donor interacts with the promoter BF3·Et2O (IM1) via the lone pair of the C3 oxygen atom, progressing through transition state TS1. Subsequent B─O bond formation weakens the C─O bond of the donor, ultimately leading to the formation of a delocalized sugar cation (IM2) upon departure of the PGOBF3− group. Glycosylation constitutes the rate‐determining step governing stereoselectivity (Figure 4d). According to the SN1‐type carbocation mechanism, the ROH acceptor may attack the anomeric C1 center from either the α‐ or β‐face. However, the presence of fluorine substitution enhances the reactivity of the delocalized carbocation, facilitating rapid nucleophilic attack. As shown in the energy profile, a notable energy difference is observed between TS3 (15.4 kcal mol−1) and TS2 (22.1 kcal mol−1). In the absence of fluorine substitution, the energy gap between corresponding transition states (TS4 and TS5) is only 1.3 kcal mol−1. Additionally, the free energies of the products (P2: −6.3 kcal mol−1; P1: −4.2 kcal mol−1) further support the preference for the α‐product in the Ferrier‐type glycosylation of difluoromethylated glyals.
3. Conclusion
To conclude, a practical Ferrier‐type glycosylation with predominant stereoselectivity was established using difluoromethylated glycal donors (18 examples), which were well‐prepared via photoredox functionalization. The proof‐of‐concept experiment emphasized the necessity of C‐2 fluoroalkylation in glycals for their subsequent stereoselective glycosylation, and a series of 35 glycosylation products with high yields and exclusive stereoselectivity, including diverse donors and acceptors, were presented. Gram‐scale synthesis and one‐pot trisaccharide assembly suggested the practicability of our method in homogeneous oligosaccharide acquisition. Subsequent control experiments and DFT investigations further demonstrated the stereoselectivity of glycosylation with regard to the solvated free energy. Given the large abundance of 2,3‐unsaturated glycosides and 2,3‐deoxyglycosides in natural products and the increasing advantages of drug fluorination, this method will have wide applicability in carbohydrate chemistry and carbohydrate‐based drugs.
Conflict of Interest
The authors declare no conflict of interest.
Author Contributions
Y.Z., H.X., and C.‐X.Z. contributed equally to this work. D.‐C.X. conceived and designed the research. Y.Z. performed experiments with the help of H.X., C.‐X.Z., and W.Z. The data were analyzed and organized by Y.Z. and C.‐X.Z. D.‐C.X., Y.Z., and C.‐X.Z. wrote the manuscript with input from all authors. D.‐C.X. and X.‐S.Y. directed the project.
Supporting information
Supporting Information
Acknowledgements
This work was financially supported by grants from the National Natural Science Foundation of China (Nos. 22177003, 22377003) and the Fundamental Research Funds for the Central Universities.
Zou Y., Xu H., Zheng C.‐X., Zhang W., Ye X.‐S., and Xiong D.‐C., “Stereoselective Ferrier‐Type O‐Glycosylation Enabled by Difluoromethylated Glycal Donors.” Adv. Sci. 13, no. 7 (2026): e19766. 10.1002/advs.202519766
Contributor Information
Xin‐Shan Ye, Email: xinshan@bjmu.edu.cn.
De‐Cai Xiong, Email: decai@bjmu.edu.cn.
Data Availability Statement
The data that support the findings of this study are available in the supplementary material of this article.
References
- 1. Taatjes D. J., Gaudiano G., Resing K., Koch T. H., J. Med. Chem. 1997, 40, 1276. [DOI] [PubMed] [Google Scholar]
- 2. Vankar Y. D., Schmidt R. R., Chem. Soc. Rev. 2000, 29, 201. [Google Scholar]
- 3. Wen W. H., Lin M. G., Su C. Y., Wang S. Y., Cheng Y. S. E., Fang J. M., Wong C. H., J. Med. Chem. 2009, 52, 4903. [DOI] [PubMed] [Google Scholar]
- 4. Ranade S. C., Demchenko A. V., J. Carbohydr. Chem. 2013, 32, 1. [Google Scholar]
- 5. Wang X. J., Zhang L., Byrne D., Nummy L., Weber D., Krishnamurthy D., Yee N., Senanayake C. H., Org. Lett. 2014, 16, 4090. [DOI] [PubMed] [Google Scholar]
- 6. Zhang B. W., Li X., Sun W. L., Xing Y., Xiu Z. L., Zhuang C. L., Dong Y. S., J. Agric. Food Chem. 2017, 65, 8319. [DOI] [PubMed] [Google Scholar]
- 7. Liu C. C., Huo C. X., Zhai C. J., Zheng X. J., Xiong D. C., Ye X. S., Bioconjug. Chem. 2022, 33, 807. [DOI] [PubMed] [Google Scholar]
- 8. Unione L., Ammerlaan A. N. A., Bosman G. P., Uslu E., Liang R., Broszeit F., van der Woude R., Liu Y., Ma S., Liu L., Gómez‐Redondo M., Bermejo I. A., Valverde P., Diercks T., Ardá A., de Vries R. P., Boons G.‐J., Nat. Commun. 2024, 15, 2979. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Shivatare S. S., Shivatare V. S., Wong C. H., Chem. Rev. 2022, 122, 15603. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Xu Z., Liu Y., Liu J., Ma W., Zhang Z., Chapla D. G., Wen L., Moremen K. W., Yi W., Li T., Nat. Chem. 2024, 16, 881. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Guerreiro A., Compañón I., Lazaris F. S., Labão‐Almeida C., Oroz P., Ghirardello M., Marques M. C., Corzana F., Bernardes G. J. L., Angew. Chem., Int. Ed. 2024, 63, 202411009. [DOI] [PubMed] [Google Scholar]
- 12. Li T., Wang A., Zhang Y., Chen W., Guo Y., Yuan X., Liu Y., Geng Y., J. Am. Chem. Soc. 2024, 146, 15155. [DOI] [PubMed] [Google Scholar]
- 13. Goodman L., Adv. Carbohydr. Chem. Biochem. 1967, 22, 109. [DOI] [PubMed] [Google Scholar]
- 14. Kim J. H., Yang H., Boons G. J., Angew. Chem., Int. Ed. 2005, 44, 947. [DOI] [PubMed] [Google Scholar]
- 15. Elferink H., Mensink R. A., White P. B., Boltje T. J., Angew. Chem., Int. Ed. 2016, 55, 11217. [DOI] [PubMed] [Google Scholar]
- 16. Smoot J. T., Pornsuriyasak P., Demchenko A. V., Angew. Chem., Int. Ed. 2005, 44, 7123. [DOI] [PubMed] [Google Scholar]
- 17. Chen J., Hansen T., Zhang Q.‐J., Liu D.‐Y., Sun Y., Yan H., Codée J. D. C., Schmidt R. R., Sun J.‐S., Angew. Chem., Int. Ed. 2019, 58, 17000. [DOI] [PubMed] [Google Scholar]
- 18. Baek J. Y., Lee B.‐Y., Jo M. G., Kim K. S., J. Am. Chem. Soc. 2009, 131, 17705. [DOI] [PubMed] [Google Scholar]
- 19. Zeng J., Wang R., Zhang S., Fang J., Liu S., Sun G., Xu B., Xiao Y., Fu D., Zhang W., Hu Y., Wan Q., J. Am. Chem. Soc. 2019, 141, 8509. [DOI] [PubMed] [Google Scholar]
- 20. Yasomanee J. P., Demchenko A. V., J. Am. Chem. Soc. 2012, 134, 20097. [DOI] [PubMed] [Google Scholar]
- 21. Pistorio S. G., Yasomanee J. P., Demchenko A. V., Org. Lett. 2014, 16, 716. [DOI] [PubMed] [Google Scholar]
- 22. Marianski M., Mucha E., Greis K., Moon S., Pardo A., Kirschbaum C., Thomas D. A., Meijer G., von Helden G., Gilmore K., Seeberger P. H., Pagel K., Angew. Chem., Int. Ed. 2020, 59, 6166. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Ma Y., Lian G., Li Y., Yu B., Chem. Comm. 2011, 47, 7515. [DOI] [PubMed] [Google Scholar]
- 24. Liu X., Song Y., Liu A., Zhou Y., Zhu Q., Lin Y., Sun H., Zhu K., Liu W., Ding N., Xie W., Sun H., Yu B., Xu P., Li W., Angew. Chem., Int. Ed. 2022, 61, 202201510. [DOI] [PubMed] [Google Scholar]
- 25. Crich D., Cai W., J. Org. Chem. 1999, 64, 4926. [DOI] [PubMed] [Google Scholar]
- 26. Crich D., Chandrasekera N. S., Angew. Chem., Int. Ed. 2004, 43, 5386. [DOI] [PubMed] [Google Scholar]
- 27. Zhu X., Kawatkar S., Rao Y., Boons G.‐J., J. Am. Chem. Soc. 2006, 128, 11948. [DOI] [PubMed] [Google Scholar]
- 28. Balmond E. I., Benito‐Alifonso D., Coe D. M., Alder R. W., McGarrigle E. M., Galan M. C., Angew. Chem., Int. Ed. 2014, 53, 8190. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Demchenko A., Stauch T., Boons G. J., Synlett 1997, 7, 818. [Google Scholar]
- 30. Liu C.‐Y. I., Mulani S., Mong K.‐K. T., Adv. Synth. Catal. 2012, 354, 3299. [Google Scholar]
- 31. Lu S. R., Lai Y. H., Chen J. H., Liu C. Y., Mong K. K. T., Angew. Chem., Int. Ed. 2011, 50, 7315. [DOI] [PubMed] [Google Scholar]
- 32. Satoh H., Hansen H. S., Manabe S., van Gunsteren W. F., Hunenberger P. H., J. Chem. Theory Comput. 2010, 6, 1783. [DOI] [PubMed] [Google Scholar]
- 33. Ishiwata A., Lee Y. J., Ito Y., Org. Biomol. Chem. 2010, 8, 3596. [DOI] [PubMed] [Google Scholar]
- 34. Nakagawa A., Tanaka M., Hanamura S., Takahashi D., Toshima K., Angew. Chem., Int. Ed. 2015, 54, 10935. [DOI] [PubMed] [Google Scholar]
- 35. Walk J. T., Buchan Z. A., Montgomery J., Chem. Sci. 2015, 6, 3448. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Ding H., Lyu J., Zhang X.‐L., Xiao X., Liu X.‐W., Nat. Commun. 2023, 14, 4010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Deng L.‐F., Wang Y., Xu S., Shen A., Zhu H., Zhang S., Zhang X., Niu D., Science 2023, 382, 928. [DOI] [PubMed] [Google Scholar]
- 38. Yang X. Y., Fu B. Q., Yu B., J. Am. Chem. Soc. 2011, 133, 12433. [DOI] [PubMed] [Google Scholar]
- 39. Kusumi S., Tomono S., Okuzawa S., Kaneko E., Ueda T., Sasaki K., Takahashi D., Toshima K., J. Am. Chem. Soc. 2013, 135, 15909. [DOI] [PubMed] [Google Scholar]
- 40. Kang J., Rhee Y. H., Org. Lett. 2021, 23, 4468. [DOI] [PubMed] [Google Scholar]
- 41. Polkowski K., Popiołkiewicz J., Krzeczyński P., Ramza J., Pucko W., Zegrocka‐Stendel O., Boryski J., Skierski J. S., Mazurek A. P., Grynkiewicz G., Cancer Lett. 2004, 203, 59. [DOI] [PubMed] [Google Scholar]
- 42. Popiołkiewicz J., Polkowski K., Skierski J. S., Mazurek A. P., Cancer Lett. 2005, 229, 67. [DOI] [PubMed] [Google Scholar]
- 43. Rusin A., Gogler A., Głowala‐Kosińska M., Bochenek D., Gruca A., Grynkiewicz G., Zawisza J., Szeja W., Krawczyk Z., Bioorg. Med. Chem. Lett. 2009, 19, 4939. [DOI] [PubMed] [Google Scholar]
- 44. Tomono S., Kusumi S., Takahashi D., Toshima K., Tetrahedron Lett. 2011, 52, 2399. [Google Scholar]
- 45. Bound D. J., Murthy P. S., Srinivas P., Food Chem. 2015, 185, 192. [DOI] [PubMed] [Google Scholar]
- 46. Ferrier R. J., Zubkov O. A., Org. React. 2004, 62, 569. [Google Scholar]
- 47. Moreno B., Quehen C., Rose‐Hélène M., Leclerc E., Quirion J.‐C., Org. Lett. 2007, 9, 2477. [DOI] [PubMed] [Google Scholar]
- 48. Gomez A. M., Lobo F., Uriel C., Lopez J. C., Eur. J. Org. Chem. 2013, 2013, 7221. [Google Scholar]
- 49. Tan H. Y., Xiang S., Leng W. L., Liu X.‐W., Adv R. S. C.. 2014, 4, 34816. [Google Scholar]
- 50. Lai M., Othman K. A., Yao H., Wang Q., Feng Y., Huang N., Liu M., Zou K., Org. Lett. 2020, 22, 1144. [DOI] [PubMed] [Google Scholar]
- 51. Ikazaki T., Ishikawa E., Tamashima H., Akiyama H., Kimuro Y., Yoritate M., Matoba H., Imamura A., Ishida H., Yamasaki S., Hirai G., Angew. Chem., Int. Ed. 2023, 62, 202302569. [DOI] [PubMed] [Google Scholar]
- 52. Ferrier R. J., Hoberg J. O., Adv. Carbohydr. Chem. Biochem. 2003, 58, 55. [DOI] [PubMed] [Google Scholar]
- 53. Rusin A., Gogler A., Głowala‐Kosińska M., Bochenek D., Gruca A., Grynkiewicz G., Zawisza J., Szeja W., Krawczyk Z., Bioorg. Med. Chem. Lett. 2009, 19, 4939. [DOI] [PubMed] [Google Scholar]
- 54. Srivastava R. M., Oliveira F. J., da Silva L. P., de Freitas Filho J. R., Oliveira S. P., Lima V. L., Carbohydr. Res. 2001, 332, 335. [DOI] [PubMed] [Google Scholar]
- 55. Di Bussolo V., Romano M. R., Pineschi M., Crotti P., Org. Lett. 2005, 7, 1299. [DOI] [PubMed] [Google Scholar]
- 56. Liu Y. X., Jiao Y., Luo H. J., Huang N. A. Y., Lai M. N., Zou K., Yao H., ACS Catal. 2021, 11, 5287. [Google Scholar]
- 57. Yao H., Zhang S. S., Leng W. L., Leow M. L., Xiang S. H., He J. X., Liao H. Z., Hoang K. L. M., Liu X. W., ACS Catal. 2017, 7, 5456. [Google Scholar]
- 58. Xiang S. H., Hoang K. L. M., He J. X., Tan Y. J., Liu X. W., Angew. Chem., Int. Ed. 2015, 54, 604. [DOI] [PubMed] [Google Scholar]
- 59. Xiang S. H., He J. X., Tan Y. J., Liu X. W., J. Org. Chem. 2014, 79, 11473. [DOI] [PubMed] [Google Scholar]
- 60. Schuff B. P., Mercer G. J., Nguyen H. M., Org. Lett. 2007, 9, 3173. [DOI] [PubMed] [Google Scholar]
- 61. Zeng J., Ma J., Xiang S., Cai S., Liu X. W., Angew. Chem., Int. Ed. 2013, 52, 5134. [DOI] [PubMed] [Google Scholar]
- 62. Xiang S., Lu Z., He J., Le Maihoang K., Zeng J., Liu X. W., Chem. 2013, 19, 14047. [DOI] [PubMed] [Google Scholar]
- 63. Xiang S., He J., Ma J., Liu X. W., Chem. Commun. 2014, 50, 4222. [DOI] [PubMed] [Google Scholar]
- 64. Herman G. A., Stevens C., Van Dyck K., Bergman A., Yi B. M., De Smet M., Snyder E., Hilliard D., Tanen M., Tanaka W., Wang A. Q., Zeng W., Musson D., Winchell G., Davies M. J., Ramael S., Gottesdiener K. M., Wagner J. A., Clin. Pharmacol. Ther. 2005, 78, 675. [DOI] [PubMed] [Google Scholar]
- 65. Walmsley S. L., Antela A., Clumeck N., Duiculescu D., Eberhard A., Gutierrez F., Hocqueloux L., Maggiolo F., Sandkovsky U., Granier C., Pappa K., Wynne B., Min S., Nichols G., Investigators S., N. Engl. J. Med. 2013, 369, 1807. [DOI] [PubMed] [Google Scholar]
- 66. Wang J., Sánchez‐Roselló M., Aceña J. L., del Pozo C., Sorochinsky A. E., Fustero S., Soloshonok V. A., Liu H., Chem. Rev. 2014, 114, 2432. [DOI] [PubMed] [Google Scholar]
- 67. Chu L. W., Chen J. Y., Wu P. C., Wu B. N., ACS Chem. Neurosci. 2015, 6, 889. [DOI] [PubMed] [Google Scholar]
- 68. Bandara H. M. H. N., Herpin M. J., Kolacny D., Harb A., Romanovicz D., Smyth H. D. C., Mol. Pharmaceut. 2016, 13, 2760. [DOI] [PubMed] [Google Scholar]
- 69. Johnson B. M., Shu Y. Z., Zhuo X. L., Meanwell N. A., J. Med. Chem. 2020, 63, 6315. [DOI] [PubMed] [Google Scholar]
- 70. Li Z., Ruan Q., Jiang Y., Wang Q., Yin G., Feng J., Zhang J., J. Med. Chem. 2024, 67, 21644. [DOI] [PubMed] [Google Scholar]
- 71. Vogl T. J., Naguib N. N. N., Nour‐Eldin N. E. A., Eichler K., Zangos S., Gruber‐Rouh T., Eur. Radiol. 2010, 20, 173. [DOI] [PubMed] [Google Scholar]
- 72. Cele Z. E. D., Somboro A. M., Amoako D. G., Ndlandla L. F., Balogun M. O., ACS Omega 2020, 5, 29657. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73. Dai Y., Hartke R., Li C., Yang Q., Liu J. O., Wang L.‐X., ACS Chem. Biol. 2020, 15, 2662. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74. Zhang M., Chen H.‐W., Liu Q.‐Q., Gao F.‐T., Li Y.‐X., Hu X.‐G., Yu C.‐Y., J. Org. Chem. 2022, 87, 1272. [DOI] [PubMed] [Google Scholar]
- 75. Yoon D. S., Liu C., Jalagam P. R., Feng J., Wang W., Swidorski J. J., Xu L., Hartz R. A., Nair S. K., Beno B. R., Panda M., Ghosh K., Kumar A., Sale H., Shah D., Mathur A., Ellsworth B. A., Cheng D., Regueiro‐Ren A., J. Med. Chem. 2024, 67, 14184. [DOI] [PubMed] [Google Scholar]
- 76. Ko K.‐S., Jaipuri F. A., Pohl N. L., J. Am. Chem. Soc. 2005, 127, 13162. [DOI] [PubMed] [Google Scholar]
- 77. Wuest F., Berndt M., Bergmann R., van den Hoff J., Pietzsch J., Bioconjug. Chem. 2008, 19, 1202. [DOI] [PubMed] [Google Scholar]
- 78. Yang H., Chan A. L., LaVallo V., Cheng Q., ACS Appl. Mater. 2016, 8, 2872. [DOI] [PubMed] [Google Scholar]
- 79. Martínez J. D., Manzano A. I., Calviño E., Diego A. d., Rodriguez de Francisco B., Romanò C., Oscarson S., Millet O., Gabius H.‐J., Jiménez‐Barbero J., Cañada F. J., J. Org. Chem. 2020, 85, 16072. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80. Popeney C. S., Rheingold A. L., Guan Z., Organometallics 2009, 28, 4452. [Google Scholar]
- 81. Liu Y.‐L., Shi T.‐D., Zhou F., Zhao X.‐L., Wang X., Zhou J., Org. Lett. 2011, 13, 3826. [DOI] [PubMed] [Google Scholar]
- 82. Cahard D., Bizet V., Chem. Soc. Rev. 2014, 43, 135. [DOI] [PubMed] [Google Scholar]
- 83. Zhou X., Malakar S., Dugan T., Wang K., Sattler A., Marler D. O., Emge T. J., Krogh‐Jespersen K., Goldman A. S., ACS Catal. 2021, 11, 14194. [Google Scholar]
- 84. Bucher C., Gilmour R., Angew. Chem., Int. Ed. 2010, 49, 8724. [DOI] [PubMed] [Google Scholar]
- 85. Sadurni A., Gilmour R., Eur. J. Org. Chem. 2018, 2018, 3684. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86. Hayashi T., Kehr G., Bergander K., Gilmour R., Angew. Chem., Int. Ed. 2019, 58, 3814. [DOI] [PubMed] [Google Scholar]
- 87. Crich D., Vinogradova O., J. Am. Chem. Soc. 2007, 129, 11756. [DOI] [PubMed] [Google Scholar]
- 88. Kurfiřt M., Červenková Št'astná L., Dračínský M., Müllerová M., Hamala V., Cuřínová P., Karban J., J. Org. Chem. 2019, 84, 6405. [DOI] [PubMed] [Google Scholar]
- 89. Kurfirt M., Lucie C. S., Curinova P., Hamala V., Karban J., J. Org. Chem. 2021, 86, 5073. [DOI] [PubMed] [Google Scholar]
- 90. DeMent P. M., Liu C., Wakpal J., Schaugaard R. N., Schlegel H. B., Nguyen H. M., ACS Catal. 2021, 11, 2108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91. Hansen T., Vermeeren P., de Jong L., Bickelhaupt F. M., Hamlin T. A., J. Org. Chem. 2022, 87, 8892. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supporting Information
Data Availability Statement
The data that support the findings of this study are available in the supplementary material of this article.
